XTX Topco Ltd Buys New Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

XTX Topco Ltd bought a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 5,333 shares of the biopharmaceutical company’s stock, valued at approximately $230,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at approximately $37,000. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at approximately $40,000. NEOS Investment Management LLC acquired a new stake in Agios Pharmaceuticals in the 4th quarter valued at approximately $210,000. North Star Asset Management Inc. acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at approximately $216,000. Finally, Northcape Wealth Management LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at approximately $244,000.

Insider Activity at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Trading Down 5.1 %

Shares of AGIO stock opened at $45.61 on Friday. The firm has a fifty day moving average price of $45.68 and a 200 day moving average price of $39.74. The company has a market cap of $2.59 billion, a P/E ratio of -7.22 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a 12 month low of $19.80 and a 12 month high of $53.28.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The company had revenue of $8.60 million during the quarter, compared to analysts’ expectations of $9.34 million. During the same period last year, the firm earned ($1.51) earnings per share. Agios Pharmaceuticals’s revenue was up 28.4% on a year-over-year basis. On average, equities analysts forecast that Agios Pharmaceuticals, Inc. will post -4.85 EPS for the current year.

Analyst Ratings Changes

Several research firms have commented on AGIO. JPMorgan Chase & Co. restated a “neutral” rating and issued a $46.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, August 5th. The Goldman Sachs Group boosted their price target on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 4th. Royal Bank of Canada restated an “outperform” rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, September 19th. Finally, Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $60.00 to $56.00 in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $52.50.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.